Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rocco Rossi

Geriatric Medicine Mashpee, MA Doctor of Osteopathy

NPI 1487966073 CMS profile 690833

483B Great Neck Rd S, Mashpee, MA 02649

Open in the dashboard

General payments

$5,983

348 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rocco Rossi of Mashpee, MA is reported in the CMS Open Payments database as having received $5,983 across 348 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17 1
2023 General $17 1
2021 General $2,031 115
2020 General $966 66
2019 General $2,952 165

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rocco Rossi
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Rocco Rossi were reported at $17. Among 512 Geriatric Medicine profiles paid that year, the median was $120 and the middle half received between $37 and $350.

Show as a table
Year Rocco Rossi Geriatric Medicine median Middle half National median
2019 $2,952 $96 $28–$339 $163
2020 $966 $99 $28–$262 $114
2021 $2,031 $94 $27–$318 $132
2022 $0 $103 $34–$338 $149
2023 $17 $109 $39–$320 $160
2024 $0 $125 $36–$371 $164
2025 $17 $120 $37–$350 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,218 88 payments
  2. Pfizer Inc. $621 48 payments
  3. Lilly USA, LLC $414 31 payments
  4. Sunovion Pharmaceuticals Inc. $369 28 payments
  5. Sanofi-Aventis U.S. LLC $300 8 payments
  6. AbbVie, Inc. $257 17 payments
  7. Amgen Inc. $246 8 payments
  8. AstraZeneca Pharmaceuticals LP $231 9 payments
  9. Astellas Pharma US Inc $220 8 payments
  10. Radius Health, Inc. $200 6 payments
  11. Other $1,908 97 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,833 344 payments
  2. Education $107 2 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $43 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $717 53 payments
  2. ELIQUIS $418 31 payments
  3. APTIOM $253 20 payments
  4. RYBELSUS $233 17 payments
  5. SOLIQUA 100/33 $227 3 payments
  6. Tresiba $210 9 payments
  7. CHANTIX $203 24 payments
  8. Tymlos $200 6 payments
  9. FARXIGA $199 7 payments
  10. AIMOVIG $183 10 payments
  11. Other $4,548 289 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

1,357

Median for Family Practice: 1,826

Drug cost

$130,546

Median for Family Practice: $120,094

Branded share of claims

20.9%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 39 $29,636
Trulicity Dulaglutide Brand 28 $27,308
Ozempic Semaglutide Brand 28 $26,828
Eliquis Apixaban Brand 20 $14,935
Janumet Sitagliptin Phos/Metformin Hcl Brand 12 $8,642
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 13 $5,439
Lisdexamfetamine Dimesylate Generic 11 $2,481
Gabapentin Generic 115 $1,577
Rosuvastatin Calcium Generic 27 $1,025
Nifedipine Er Nifedipine Brand 39 $864

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$3,851

Medicare's payments for the services billed

Medicare patients

41

Average age 73

Services billed

72

24 women, 17 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 54%
Diabetes 46%
Heart failure 29%
Ischemic heart disease 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

348 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record